Search research articles
Contact Us
Filters
Showing results (31-40 of 120) with videos related to
Page
of 12
Sort By:
European Heart Journal
|
June 6, 2018
PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
Angela Pirillo, Alberico Luigi Catapano
Drug Design, Development and Therapy
|
April 28, 2015
Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3
Angela Pirillo, Alberico Luigi Catapano
Current Opinion in Lipidology
|
November 5, 2025
The two faces of cholesteryl ester transfer protein inhibitors
Angela Pirillo, Alberico L Catapano
Pharmacological Research
|
June 4, 2023
The burden of hypercholesterolemia and ischemic heart disease in an ageing world
Angela Pirillo, Giuseppe Danilo Norata
Biochemical and Biophysical Research Communications
|
November 25, 2010
Dual effect of hypochlorite in the modification of high density lipoproteins
Angela Pirillo, Patrizia Uboldi, Alberico L Catapano
Current Atherosclerosis Reports
|
March 2, 2024
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
Angela Pirillo, Lale Tokgözoğlu, Alberico L Catapano
Clinical Pharmacology and Therapeutics
|
December 7, 2018
Lipid Lowering and Incidence of Cataract, a Role for Fibrates
Manuela Casula, Angela Pirillo, Alberico L Catapano
Current Atherosclerosis Reports
|
December 26, 2025
Fibrates : Do They Still Have a Role in Therapy in 2025?
Angela Pirillo, Alberto Zambon, Alberico L Catapano
European Heart Journal
|
November 8, 2023
Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
Lale Tokgözoğlu, Angela Pirillo, Alberico Luigi Catapano
Current Atherosclerosis Reports
|
April 30, 2025
Oral PCSK9 Inhibitors: Will They Work?
Lale Tokgözoğlu, Angela Pirillo, Alberico L Catapano
Page
of 12
Search research articles
Search
Showing results (31-40 of 120) with videos related to
Sort By:
Page
of 12
European Heart Journal
|
June 6, 2018
PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?
Angela Pirillo, Alberico Luigi Catapano
Drug Design, Development and Therapy
|
April 28, 2015
Update on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3
Angela Pirillo, Alberico Luigi Catapano
Current Opinion in Lipidology
|
November 5, 2025
The two faces of cholesteryl ester transfer protein inhibitors
Angela Pirillo, Alberico L Catapano
Pharmacological Research
|
June 4, 2023
The burden of hypercholesterolemia and ischemic heart disease in an ageing world
Angela Pirillo, Giuseppe Danilo Norata
Biochemical and Biophysical Research Communications
|
November 25, 2010
Dual effect of hypochlorite in the modification of high density lipoproteins
Angela Pirillo, Patrizia Uboldi, Alberico L Catapano
Current Atherosclerosis Reports
|
March 2, 2024
European Lipid Guidelines and Cardiovascular Risk Estimation: Current Status and Future Challenges
Angela Pirillo, Lale Tokgözoğlu, Alberico L Catapano
Clinical Pharmacology and Therapeutics
|
December 7, 2018
Lipid Lowering and Incidence of Cataract, a Role for Fibrates
Manuela Casula, Angela Pirillo, Alberico L Catapano
Current Atherosclerosis Reports
|
December 26, 2025
Fibrates : Do They Still Have a Role in Therapy in 2025?
Angela Pirillo, Alberto Zambon, Alberico L Catapano
European Heart Journal
|
November 8, 2023
Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials
Lale Tokgözoğlu, Angela Pirillo, Alberico Luigi Catapano
Current Atherosclerosis Reports
|
April 30, 2025
Oral PCSK9 Inhibitors: Will They Work?
Lale Tokgözoğlu, Angela Pirillo, Alberico L Catapano
Page
of 12